CORVUS PHARMACEUTICALS INC (CRVS)
US2210151005 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to CRVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.33. This target is 14.5% above the current price.
CRVS was analyzed by 11 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about CRVS.
In the previous month the buy percentage consensus was at a similar level.
CRVS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-09-16 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-05-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-03-27 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-16 | Mizuho | Reiterate | Neutral -> Neutral |
| 2023-05-30 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-05-09 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2022-10-07 | Ladenburg Thalmann | Initiate | Buy |
| 2021-12-03 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-12-01 | Jefferies | Initiate | Buy |
| 2021-08-03 | Mizuho | Maintains | Neutral |
| 2021-07-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-27 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-03-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-10 | Mizuho | Downgrade | Buy -> Neutral |